Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$30.28 +5.5%	$26.59	$23.15 ▼ $129.39	$11.10B	1.84	8.64 million shs	14.69 million shs
TAK Takeda Pharmaceutical	$15.44 +0.5%	$14.85	$12.80 ▼ $15.53	$48.91B	0.23	1.98 million shs	1.46 million shs
TEVA Teva Pharmaceutical Industries	$17.07 +2.6%	$16.90	$12.47 ▼ $22.80	$19.09B	0.6	10.22 million shs	10.81 million shs
VTRS Viatris	$9.34 +1.7%	$8.72	$6.85 ▼ $13.55	$10.77B	0.89	10.99 million shs	11.64 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	+5.54%	+12.73%	+11.94%	+17.68%	-74.14%
TAK Takeda Pharmaceutical	+0.39%	+3.07%	+2.49%	+1.68%	+18.50%
TEVA Teva Pharmaceutical Industries	+2.52%	+0.41%	-1.07%	+14.99%	+3.02%
VTRS Viatris	+1.74%	+5.06%	+7.48%	+14.46%	-10.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRNA Moderna	4.3651 of 5 stars	4.0	2.0	0.0	4.6	1.2	2.5	0.6
TAK Takeda Pharmaceutical	1.2491 of 5 stars	0.0	3.0	2.5	0.0	2.6	0.0	0.6
TEVA Teva Pharmaceutical Industries	4.0821 of 5 stars	4.6	3.0	0.0	0.0	2.1	1.7	1.9
VTRS Viatris	3.0627 of 5 stars	1.9	5.0	2.5	0.0	2.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNA Moderna	2.04	Hold	$46.61	53.93% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	41.33% Upside
VTRS Viatris	1.80	Reduce	$10.40	11.35% Upside

Current Analyst Ratings Breakdown

Latest VTRS, TAK, MRNA, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/6/2025	VTRS Viatris	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$10.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $70.00
5/2/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $40.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNA Moderna	$3.24B	3.62	N/A	N/A	$28.33 per share	1.07
TAK Takeda Pharmaceutical	$30.09B	1.63	$3.20 per share	4.83	$14.39 per share	1.07
TEVA Teva Pharmaceutical Industries	$16.54B	1.18	$3.45 per share	4.95	$4.74 per share	3.60
VTRS Viatris	$14.74B	0.74	$5.19 per share	1.80	$15.61 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	70.19	9.36	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.49	0.85	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)
VTRS Viatris	-$634.20M	-$3.17	N/A	3.63	N/A	-26.45%	16.20%	7.01%	8/7/2025 (Estimated)

Latest VTRS, TAK, MRNA, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/8/2025	Q1 2025	VTRS Viatris	$0.49	$0.50	+$0.01	-$2.55	$3.30 billion	$3.25 billion
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.56%	N/A	250.00%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
VTRS Viatris	$0.48	5.14%	N/A	N/A	N/A

Latest VTRS, TAK, MRNA, and TEVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/5/2025	VTRS Viatris	quarterly	$0.12	5.55%	5/23/2025	5/23/2025	6/16/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNA Moderna	N/A	4.22	4.14
TAK Takeda Pharmaceutical	0.57	1.01	0.52
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74
VTRS Viatris	1.02	1.68	0.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRNA Moderna	75.33%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
MRNA Moderna	11.00%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.49%
VTRS Viatris	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable
VTRS Viatris	32,000	1.17 billion	1.17 billion	Optionable

VTRS, TAK, MRNA, and TEVA Headlines

Recent News About These Companies

The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call

June 27, 2025 | msn.com

Viatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

June 26, 2025 | finanznachrichten.de

Theravance higher as China approves Viatris-partnered COPD therapy

June 26, 2025 | msn.com

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

June 26, 2025 | prnewswire.com

Viatris: The Problem With The Business Model

June 25, 2025 | seekingalpha.com

3 Reasons to Avoid VTRS and 1 Stock to Buy Instead

June 17, 2025 | msn.com

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

June 12, 2025 | prnewswire.com

Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm

June 10, 2025 | globenewswire.com

VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review

June 10, 2025 | msn.com

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 9, 2025 | seekingalpha.com

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

June 9, 2025 | zacks.com

Goldman Sachs Initiates Coverage of Viatris (VTRS) with Neutral Recommendation

June 7, 2025 | msn.com

Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout

June 6, 2025 | insidermonkey.com

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

June 5, 2025 | seekingalpha.com

Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights

June 3, 2025 | businesswire.com

DEADLINE ALERT for VTRS and CGC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 3, 2025 | globenewswire.com

Class Action Filed Against Viatris Inc. (VTRS) Over Securities Violations - Contact Levi & Korsinsky Today

June 3, 2025 | accessnewswire.comA

VTRS DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS

June 3, 2025 | accessnewswire.comA

Class Action Lawsuit Filed: Viatris Inc. (VTRS) - Join by June 3, 2025 - Contact Levi & Korsinsky

June 3, 2025 | accessnewswire.comA

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Viatris Inc. (VTRS)

June 3, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?

VTRS, TAK, MRNA, and TEVA Company Descriptions

Moderna NASDAQ:MRNA

$30.28 +1.59 (+5.54%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$30.60 +0.32 (+1.06%)

As of 04:04 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Takeda Pharmaceutical NYSE:TAK

$15.44 +0.07 (+0.46%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$15.44 0.00 (-0.03%)

As of 04:05 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$17.07 +0.43 (+2.58%)

Closing price 07/2/2025 03:59 PM Eastern

Extended Trading

$17.18 +0.11 (+0.62%)

As of 04:02 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Viatris NASDAQ:VTRS

$9.34 +0.16 (+1.74%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$9.32 -0.02 (-0.19%)

As of 04:05 AM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time